title: Cyclic hormonal replacement therapy after the menopause: transdermal versus oral treatment.
abstract: In an open, randomized, comparative, between-patient trial, 45 postmenopausal women were treated for 4 months with cyclical transdermal oestradiol 0.05 mg per day or oral conjugated equine oestrogens 0.625 mg per day, in both cases, plus, medroxyprogesterone acetate 10 mg per day on the last 8 days of each cycle. Similar relief from postmenopausal symptoms was obtained with both treatments. Post-treatment histological evaluation of the endometrium did not reveal neoplastic or hyperplastic change in any patient. Early follicular-phase plasma oestradiol levels were observed only after transdermal oestradiol. There was a significant reduction in serum total cholesterol and LDL cholesterol in both treatment groups, with no difference between treatments, whereas serum triglyceride levels were decreased only by transdermal oestradiol. Plasma calcium and phosphorus fell significantly and serum intact parathyroid hormone rose significantly, with no difference between the therapies. No significant changes were observed in clotting factors. Transdermal oestradiol appears to be an effective and safe hormonal replacement therapy, and this route of administration may be responsible for the more useful action of the drug on serum lipids and plasma oestradiol levels.
authors.affiliation: Istituto di Medicina Interna, Università di Milano, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Cortellaro
authors.forename: T
authors.initials: T
authors.lastname: Nencioni
authors.forename: C
authors.initials: C
authors.lastname: Boschetti
authors.forename: S
authors.initials: S
authors.lastname: Ortolani
authors.forename: F
authors.initials: F
authors.lastname: Buzzi
authors.forename: B
authors.initials: B
authors.lastname: Francucci
authors.forename: M P
authors.initials: MP
authors.lastname: Caraceni
authors.forename: P
authors.initials: P
authors.lastname: Abelli
authors.forename: F
authors.initials: F
authors.lastname: Polvani
authors.forename: C
authors.initials: C
authors.lastname: Zanussi
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D000328:Adult; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000008:administration & dosage* / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000008:administration & dosage* / Q000627:therapeutic use; D008593:Menopause / Q000187:drug effects*; D008875:Middle Aged
chemical_list: D004966:Estrogens, Conjugated (USP); D004958:Estradiol; D008525:Medroxyprogesterone